111 related articles for article (PubMed ID: 12528799)
1. In vitro chemosensitivity testing of hematological cancer patients: detection of ornithine decarboxylase.
Bachrach U; Wang Y
Recent Results Cancer Res; 2003; 161():62-70. PubMed ID: 12528799
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of ornithine decarboxylase as a measure of chemosensitivity testing.
Bachrach U
Methods Mol Med; 2005; 110():197-211. PubMed ID: 15901937
[TBL] [Abstract][Full Text] [Related]
3. In vitro chemosensitivity testing of hematological cancers: immunohistochemical detection of ornithine decarboxylase.
Wang Y; Ashkenazi YJ; Bachrach U
Anticancer Drugs; 1999 Oct; 10(9):797-805. PubMed ID: 10587289
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of ornithine decarboxylase in individual cells: potential application for in vitro chemosensitivity assays.
Shayovits A; Bachrach U
J Histochem Cytochem; 1994 May; 42(5):607-11. PubMed ID: 8157932
[TBL] [Abstract][Full Text] [Related]
5. In vitro development and validation of a non-invasive (13)C-stable isotope assay for ornithine decarboxylase.
Jaenisch S; Squire M; Butler R; Yazbeck R
J Breath Res; 2016 May; 10(2):026009. PubMed ID: 27137347
[TBL] [Abstract][Full Text] [Related]
6. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
7. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM; Grecu OM; Stier U; Gilster TJ; Janát MM; Untch M; Konecny G; Bruckner HW; Cree IA
Recent Results Cancer Res; 2003; 161():221-30. PubMed ID: 12528810
[TBL] [Abstract][Full Text] [Related]
8. Alterations in ornithine decarboxylase and transglutaminase activities in lymphocytes from untreated patients with chronic lymphocytic leukemia.
Vanella A; Campisi A; Guglielmo P; Cacciola E; Cunsolo F; Geremia E; Tiriolo P; Pappalardo P; Crisafi G
Acta Haematol; 1986; 76(1):33-6. PubMed ID: 2878557
[TBL] [Abstract][Full Text] [Related]
9. Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine.
Levin VA; Jochec JL; Shantz LM; Koch PE; Pegg AE
J Histochem Cytochem; 2004 Nov; 52(11):1467-74. PubMed ID: 15505341
[TBL] [Abstract][Full Text] [Related]
10. [Progress of individualized chemotherapy guided by chemosensitivity test].
Mi YJ; Zhang CZ; Fu LW
Yao Xue Xue Bao; 2009 Nov; 44(11):1187-92. PubMed ID: 21355317
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP; Averette HE; Donato DM; Penalver M
Cancer; 1993 Feb; 71(4 Suppl):1613-20. PubMed ID: 8431897
[TBL] [Abstract][Full Text] [Related]
12. Ornithine decarboxylase (ODC) as a prognostic factor in operable breast cancer.
Love RR; Astrow SH; Cheeks AM; Havighurst TC
Breast Cancer Res Treat; 2003 Jun; 79(3):329-34. PubMed ID: 12846417
[TBL] [Abstract][Full Text] [Related]
13. [Chemosensitivity testing in ovarian cancer--prospects for the future].
Pogońska P; Wydra D; Serkies K; Kobierski J; Łojkowska A
Ginekol Pol; 2014 Sep; 85(9):695-8. PubMed ID: 25322542
[TBL] [Abstract][Full Text] [Related]
14. N-ω-chloroacetyl-L-ornithine has in-vitro activity against cancer cell lines and in-vivo activity against ascitic and solid tumors.
Vargas-Ramírez AL; Medina-Enríquez MM; Cordero-Rodríguez NI; Ruiz-Cuello T; Aguilar-Faisal L; Trujillo-Ferrara JG; Alcántara-Farfán V; Rodríguez-Páez L
Anticancer Drugs; 2016 Jul; 27(6):508-18. PubMed ID: 26918391
[TBL] [Abstract][Full Text] [Related]
15. N-ω-chloroacetyl-l-ornithine, a new competitive inhibitor of ornithine decarboxylase, induces selective growth inhibition and cytotoxicity on human cancer cells versus normal cells.
Medina-Enríquez MM; Alcántara-Farfán V; Aguilar-Faisal L; Trujillo-Ferrara JG; Rodríguez-Páez L; Vargas-Ramírez AL
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):345-53. PubMed ID: 24939101
[TBL] [Abstract][Full Text] [Related]
16. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood leucocytes ornithine decarboxylase activity in chronic myeloid leukemia patients: prognostic and therapeutic implications.
Tripathi AK; Chaturvedi R; Ahmad R; Asim M; Sawlani KK; Singh RL; Tekwani BL
Leuk Res; 2002 Apr; 26(4):349-54. PubMed ID: 11839377
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitivity testing in malignant melanoma.
Ugurel S; Tilgen W; Reinhold U
Recent Results Cancer Res; 2003; 161():81-92. PubMed ID: 12528801
[TBL] [Abstract][Full Text] [Related]
19. Ornithine decarboxylase attenuates leukemic chemotherapy drugs-induced cell apoptosis and arrest in human promyelocytic HL-60 cells.
Hsu PC; Hung HC; Liao YF; Liu CC; Tsay GJ; Liu GY
Leuk Res; 2008 Oct; 32(10):1530-40. PubMed ID: 18339422
[TBL] [Abstract][Full Text] [Related]
20. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis.
Sharma S; Stutzman JD; Kelloff GJ; Steele VE
Cancer Res; 1994 Nov; 54(22):5848-55. PubMed ID: 7954413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
